A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients

Clinical Infectious Diseases

Volumn 57, Issue 1, 2013, Pages 21-31

  Pasipanodya, Jotam G ^a   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

acquired drug resistance; directly observed therapy; microbiologic failure; self administered therapy; tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; CHEMOTHERAPY; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE; DRUG SELF ADMINISTRATION; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LUNG TUBERCULOSIS; META ANALYSIS; PRIORITY JOURNAL; RELAPSE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ACQUIRED DRUG RESISTANCE; DIRECTLY OBSERVED THERAPY; MICROBIOLOGIC FAILURE; SELF-ADMINISTERED THERAPY; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, BACTERIAL; HUMANS; MEDICATION ADHERENCE; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; SELF ADMINISTRATION; TREATMENT FAILURE; TUBERCULOSIS;

EID: 84878839292     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit167     Document Type: Article

References (39)

1. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City-turning the tide. N Engl J Med 1995; 333:229-33.
2. Fujiwara PI, Larkin C, Frieden TR. Directly observed therapy in New York City: history, implementation, results, and challenges. Clin Chest Med 1997; 18:135-48. (Pubitemid 27152511)
3. No authors listed. Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. China Tuberculosis Control Collaboration. Lancet 1996; 347:358-62.
4. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179-84. (Pubitemid 24121986)
5. Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 2001; 357:664-9. (Pubitemid 32206424)
6. Steffen R, Menzies D, Oxlade O, et al. Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLoS One 2010; 5:e14014.
7. Ormerod LP. Directly observed therapy (DOT) for tuberculosis: why, when, how and if? Thorax 1999; 54(suppl 2):S42-5. (Pubitemid 29341394)
8. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998; 279:943-8. (Pubitemid 28136084)
9. Frieden TR, Sbarbaro JA. Promoting adherence to treatment for tuberculosis: the importance of direct observation. World Hosp Health Serv 2007; 43:30-3.
10. Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. Costeffectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996; 154:1013-9.
11. Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Noncompliance with directly observed therapy for tuberculosis: epidemiology and effect on the outcome of treatment. Chest 1997; 111:1168-73. (Pubitemid 27200067)
12. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet 2004; 364:417-22.
13. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2007; CD003343.
14. Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 2008; 336:484-7. (Pubitemid 351350598)
15. Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171:1430-5. (Pubitemid 40800517)
16. Charalambous S, Grant AD, Moloi V, et al. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2008; 12:942-8.
17. Dartois V. Drug forgiveness and interpatient pharmacokinetic variability in tuberculosis. J Infect Dis 2011; 204:1827-9.
18. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrugresistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204:1951-9.
19. Gumbo T. General principles of chemotherapy of infectious diseases. In: Brunton LL, Chabner B, Knollmann B, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York, NY: McGraw-Hill Medical, 2011.
20. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5:213-5.
21. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12. (Pubitemid 26120810)
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
23. Borenstein M, Hedges LV, Higgins JT, Rothstein HR. Introduction to meta-analysis.WestWessex, UK: JohnWiley & Sons, 2009.
24. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998; 351:47-52. (Pubitemid 28020173)
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-88. (Pubitemid 17189972)
26. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2:121-45.
27. Ormerod LP, Horsfield N, Green RM. Tuberculosis treatment outcome monitoring: Blackburn 1988-2000. Int J Tuberc Lung Dis 2002; 6:662-5. (Pubitemid 34832144)
28. Pungrassami P, Johnsen SP, Chongsuvivatwong V, Olsen J. Has directly observed treatment improved outcomes for patients with tuberculosis in southern Thailand? Trop Med Int Health 2002; 7:271-9. (Pubitemid 34264380)
29. Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 2004; 170:561-6. (Pubitemid 39209140)
30. Okanurak K, Kitayaporn D, Wanarangsikul W, Koompong C. Effectiveness of DOT for tuberculosis treatment outcomes: a prospective cohort study in Bangkok, Thailand. Int J Tuberc Lung Dis 2007; 11:762-8. (Pubitemid 47056985)
31. Anuwatnonthakate A, Limsomboon P, Nateniyom S, et al. Directly observed therapy and improved tuberculosis treatment outcomes in Thailand. PLoS One 2008; 3:e3089.
32. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998; 352:1340-3. (Pubitemid 28510914)
33. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. Int J Tuberc Lung Dis 2000; 4:550-4. (Pubitemid 30409172)
34. Tuberculosis Research Centre. A controlled clinical trial of oral shortcourse regimens in the treatment of sputum-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 1997; 1:509-17.
35. Kamolratanakul P, Sawert H, Lertmaharit S, et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999; 93:552-7. (Pubitemid 29495849)
36. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32:851-4. (Pubitemid 32524817)
37. van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ 2011; 89:632-9.
38. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55:169-77.
39. Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977; 105:488-95. (Pubitemid 8112070)